SHORT HILLS, N.J.--(BUSINESS WIRE)--April 6, 2006--Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC - News) announced today that Spiro Rombotis, President and Chief Executive Officer, will present an overview of the Company and its pipeline at the Biotechnology Industry Organization's (BIO) 2006 Annual International Convention in Chicago. Cyclacel, which began trading on the Nasdaq National Market on March 28, is focused on the discovery and development of small molecule cell cycle inhibitors for the treatment of cancer and other serious diseases. The Company's pipeline includes seliciclib (CYC202) and sapacitabine (CYC682), in clinical trials for the treatment of cancer, a third compound in late preclinical development, a large portfolio of development candidates, and a productive drug discovery engine. Mr. Rombotis' presentation will take place on Tuesday, April 11, 2006 at 10:45 am Central Time in Room C, McCormick Place South, Level 3 Exhibit Hall A of the McCormick Place Convention Center, 2301 South Lake Shore Drive, Chicago, IL.
